Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3960907 | 0.90 | KMT2A (0.62) | KMT2ASLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL30141105 | 0.90 | KMT2A (0.62) | KMT2ASLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL2705973 | 0.87 | TTR (0.64) | KMT2ARAB9ANPC1SMN1; SMN2SMPD1 | |
| SCHEMBL873776 | 0.85 | SMPD1 (0.70) | KMT2ASLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL12114405 | 0.84 | KMT2A (0.54) | KMT2ASLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL2087641 | 0.82 | NPC1 (0.71) | KMT2ASLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL1647432 | 0.82 | TDP1 (0.58) | KMT2ASLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL22015271 | 0.82 | LMNA (0.62) | KMT2ASLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL3960881 | 0.82 | LMNA (0.62) | KMT2ASLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL23226754 | 0.81 | FFAR4 (0.59) | KMT2ASLC6A2SLC6A3TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435037-A1 | HIV PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-04-04 | — | — | EP | disclosed |
| EP-2435462-A1 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS | Pfizer Limited (GB) | 2012-04-04 | — | — | EP | disclosed |
| WO-2010136940-A1 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS | PFIZER LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136940-A1 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS | PFIZER LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138338-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | GLOSSOP PAUL ALAN | 2010-12-02 | — | — | US | disclosed |
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | GLOSSOP PAUL ALAN | 2010-12-02 | — | — | US | disclosed |
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | GLOSSOP PAUL ALAN | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | NR3C1, NR3C2, MC2R | KMT2A 4072/4885SLC6A2 3833/4885SLC6A3 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.